Age and research-use confirmation
Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
Evidence tiers, how to read the badges
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A stabilized synthetic analog of GHRH(1-44) that resists DPP-IV degradation, FDA approved to reduce excess visceral abdominal fat in HIV associated lipodystrophy.
A GHRH analog paired with a selective ghrelin receptor agonist, combined to synergistically stimulate pulsatile growth hormone release.
The GHRH(1-29) fragment, the shortest fully active GHRH sequence, used to stimulate physiologic, pulsatile growth hormone secretion.
An orally active non peptide ghrelin receptor agonist that reliably raises GH and IGF-1, studied across GH deficiency, sarcopenia, and aging, with a notable cardiac safety flag.
A family of synthetic ghrelin mimetic GH releasing peptides acting on GHS-R1a, varying in GH potency, appetite stimulation, and cortisol/prolactin effect.
For Research Use Only. Not for human or animal consumption. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Fnx Labs LLC | Fnx Performance
Support email: support@fnxperformancelabs.com
Support phone: 808-620-1169
Business address:
2343 W 227th St
Torrance, CA 90501
United States